Carl Zeiss Meditec Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Markus Weber
Chief executive officer
€1.3m
Total compensation
| CEO salary percentage | 23.1% |
| CEO tenure | 1.4yrs |
| CEO ownership | n/a |
| Management average tenure | 3.2yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | €278m |
| Dec 31 2022 | n/a | n/a | €307m |
| Sep 30 2022 | €1m | €298k | €294m |
Compensation vs Market: Markus's total compensation ($USD1.39M) is below average for companies of similar size in the MX market ($USD5.70M).
Compensation vs Earnings: Insufficient data to compare Markus's compensation with company performance.
CEO
Markus Weber
1.4yrs
Tenure
€1,289,067
Compensation
Dr. Markus Weber is CEO & Chairman of Management Board of Carl Zeiss Meditec AG from January 01, 2022 and served as its President since January 01, 2022 until December 2022. He joined ZEISS Semiconductor M...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman of Management Board | 1.4yrs | €1.29m | no data | |
| CFO & Member of the Management Board | 4.7yrs | €1.11m | no data | |
| Director of Investor Relations | no data | no data | no data | |
| Chief Medical Officer for Global Ophthalmic Devices | 6.7yrs | no data | no data | |
| Head of Sales for Ophthalmic Devices & President of Carl Zeiss Meditec | 3.3yrs | no data | no data | |
| President of Ophthalmic Devices and Head of the Ophthalmic Devices Strategic & Digital Business Unit | 3.1yrs | no data | no data | |
| Head of the Microsurgery Strategic Business Unit - ZEISS Medical Technology | no data | no data | no data | |
| Head of Global Regulatory & Clinical Affairs | less than a year | no data | no data |
3.2yrs
Average Tenure
58yo
Average Age
Experienced Management: AFX N's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Head of Global Regulatory & Clinical Affairs | less than a year | no data | no data | |
| Chairman of the Supervisory Board | 3yrs | no data | no data | |
| Honorary Chairman of the Supervisory Board | 2.1yrs | €43.10k | no data | |
| Member of the Supervisory Board | 3yrs | €38.00k | no data | |
| Member of Supervisory Board | 4.3yrs | no data | no data | |
| Member of the Supervisory Board | 2.1yrs | €20.70k | no data | |
| Employee Representative Member of the Supervisory Board | less than a year | no data | no data | |
| Member of the Supervisory Board | 5.2yrs | €52.00k | no data | |
| Employee Representative Deputy Chairman of Supervisory Board | 3.7yrs | €36.00k | no data | |
| Employee Representative Member of Supervisory Board | 3.3yrs | €36.00k | no data | |
| Member of Supervisory Board | 2.1yrs | no data | no data | |
| Employee Representative Member of the Supervisory Board | 1.3yrs | no data | no data |
2.5yrs
Average Tenure
53yo
Average Age
Experienced Board: AFX N's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/13 01:21 |
| End of Day Share Price | 2023/03/16 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Carl Zeiss Meditec AG is covered by 32 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pierre-Yves Gauthier | AlphaValue |
| Samuel England | Berenberg |
| Scott Bardo | Berenberg |